biostudies-literatureUnknown6(1)Zhang YThis retrospective study investigated the association between the pattern of disease progression and molecular mechanism of acquired resistance in a large cohort of 49 patients with ROS1-rearranged advanced non-small-cell lung cancer treated with first-line crizotinib. We found that treatment-emergent ROS1 point mutations were the major molecular mechanism of crizotinib resistance, particularly for patients who developed extracranial-only disease progression. Our findings highlight the importance of rebiopsy and gene testing for subsequent-line therapeutic management.NPJ precision oncology20https://www.ebi.ac.uk/biostudies/studies/S-EPMC8971474biostudies-literatureDisease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.PMC8971474Yang HLizaso ALiu JZeng LYang NXu QXu CLi YHuang ZZhang YZhang XWang WSong ZOu SIfalseDisease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.This retrospective study investigated the association between the pattern of disease progression and molecular mechanism of acquired resistance in a large cohort of 49 patients with ROS1-rearranged advanced non-small-cell lung cancer treated with first-line crizotinib. We found that treatment-emergent ROS1 point mutations were the major molecular mechanism of crizotinib resistance, particularly for patients who developed extracranial-only disease progression. Our findings highlight the importance of rebiopsy and gene testing for subsequent-line therapeutic management.2022-01-01T00:00:00Z2022 Mar2025-04-19T17:38:05.283Z2025-04-19T17:38:05.283ZS-EPMC89714743536187010.1038/s41698-022-00264-w